Celgene Corp.'s hopes of becoming a force in inflammatory bowel disease have been helped by positive results from a mid-stage trial evaluating its psoriasis blockbuster Otezla (apremilast) for ulcerative colitis (UC).
Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success
The big-selling psoriasis drug has achieved healthy clinical remission rates in a Phase II trial for ulcerative colitis, and Celgene believes Otezla and another potential blockbuster, ozanimod, will help it build a significant presence in inflammatory bowel disease.
More from Alimentary/Metabolic
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Therapy Areas
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.